ARQT - Arcutis Biotherapeutics Reveals Promising Data From Lead Drug In Pediatric Patients With Atopic Dermatitis | Benzinga
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced that the INTEGUMENT-PED Phase 3 trial of roflumilast cream 0.05%, in children ages 2 to 5 years with mild to moderate atopic dermatitis met its primary endpoint and all secondary endpoints.
For the primary endpoint, 25.4% of children treated once daily with roflumilast cream achieved Investigator Global Assessment (IGA) Success compared to 10.7% of ...